These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38218209)

  • 1. Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
    Kreins AY; Roux E; Pang J; Cheng I; Charles O; Roy S; Mohammed R; Owens S; Lowe DM; Brugha R; Williams R; Howley E; Best T; Davies EG; Worth A; Solas C; Standing JF; Goldstein RA; Rocha-Pereira J; Breuer J
    Clin Immunol; 2024 Feb; 259():109901. PubMed ID: 38218209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favipiravir elicits antiviral mutagenesis during virus replication in vivo.
    Arias A; Thorne L; Goodfellow I
    Elife; 2014 Oct; 3():e03679. PubMed ID: 25333492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
    Abdelnabi R; Morais ATS; Leyssen P; Imbert I; Beaucourt S; Blanc H; Froeyen M; Vignuzzi M; Canard B; Neyts J; Delang L
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.
    Komeno T; Furuta Y; Nakajima N; Tani H; Morinaga Y
    Antiviral Res; 2022 Sep; 205():105387. PubMed ID: 35931138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of resistance to favipiravir in influenza.
    Goldhill DH; Te Velthuis AJW; Fletcher RA; Langat P; Zambon M; Lackenby A; Barclay WS
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):11613-11618. PubMed ID: 30352857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.
    Delang L; Segura Guerrero N; Tas A; Quérat G; Pastorino B; Froeyen M; Dallmeier K; Jochmans D; Herdewijn P; Bello F; Snijder EJ; de Lamballerie X; Martina B; Neyts J; van Hemert MJ; Leyssen P
    J Antimicrob Chemother; 2014 Oct; 69(10):2770-84. PubMed ID: 24951535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
    Padhi AK; Dandapat J; Saudagar P; Uversky VN; Tripathi T
    FEBS Lett; 2021 Sep; 595(18):2366-2382. PubMed ID: 34409597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
    Furuta Y; Komeno T; Nakamura T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):449-463. PubMed ID: 28769016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Santos-Ferreira N; Van Dycke J; Chiu W; Neyts J; Matthijnssens J; Rocha-Pereira J
    Antiviral Res; 2024 Mar; 223():105839. PubMed ID: 38373532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity.
    Lewis MA; Cortés-Penfield NW; Ettayebi K; Patil K; Kaur G; Neill FH; Atmar RL; Ramani S; Estes MK
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0063623. PubMed ID: 37787556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Favipiravir, a new concept of antiviral drug against influenza viruses].
    Reina J; Reina N
    Rev Esp Quimioter; 2017 Apr; 30(2):79-83. PubMed ID: 28176519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential and action mechanism of favipiravir as an antiviral against Junin virus.
    Zadeh VR; Afowowe TO; Abe H; Urata S; Yasuda J
    PLoS Pathog; 2022 Jul; 18(7):e1010689. PubMed ID: 35816544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses.
    Delang L; Abdelnabi R; Neyts J
    Antiviral Res; 2018 May; 153():85-94. PubMed ID: 29524445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
    Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
    Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenesis in Norovirus in Response to Favipiravir Treatment.
    Ruis C; Brown LK; Roy S; Atkinson C; Williams R; Burns SO; Yara-Romero E; Jacobs M; Goldstein R; Breuer J; Lowe DM
    N Engl J Med; 2018 Nov; 379(22):2173-2176. PubMed ID: 30485769
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
    Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
    Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.
    Baranovich T; Wong SS; Armstrong J; Marjuki H; Webby RJ; Webster RG; Govorkova EA
    J Virol; 2013 Apr; 87(7):3741-51. PubMed ID: 23325689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
    Shiraki K; Daikoku T
    Pharmacol Ther; 2020 May; 209():107512. PubMed ID: 32097670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.